Core Viewpoint - The launch of the new generation all-femtosecond CLEAR Pro technology represents a significant advancement in the field of ophthalmology, particularly in refractive surgery, addressing the limitations of traditional platforms and enhancing personalized treatment options for astigmatism correction [1][20]. Group 1: Technology and Innovation - The CLEAR (Corneal Lens Extraction) technique allows for customized vision correction by analyzing individual corneal topography, astigmatism distribution, and higher-order aberrations, thus improving post-operative visual quality, especially at night [3][9]. - The Z8 device used in the CLEAR procedure features automatic lens positioning, significantly reducing vertical coma risk and achieving micron-level precision in positioning [9][10]. - The Z8 system's dual-tunnel guiding mechanism reduces intra-stromal operations by 40%, leading to a 35% decrease in inflammatory responses [10][12]. Group 2: Clinical Outcomes and Efficacy - Clinical data indicates that 90% of patients achieved 20/20 vision or better one month post-surgery, with 100% of patients within ±0.50D of equivalent spherical power, showcasing the advantages of the CLEAR procedure over other platforms [15]. - The CLEAR technique has demonstrated an 83% reduction in the incidence of coma aberrations and a 22% decrease in corneal tissue loss, highlighting its effectiveness [10][12]. Group 3: Market Position and Future Outlook - Ziemer, having focused on the lens extraction market for a decade, aims to leverage the CLEAR technology to address existing challenges and set new industry standards [7][17]. - The introduction of the CLEAR Pro technology is expected to enhance the accessibility and sophistication of refractive surgery, allowing more patients to benefit from improved vision correction solutions [20].

Group 1 - The first National Eye Health Science Popularization Seminar was held in Ningbo, focusing on myopia prevention and eye health education [1] - The theme of the seminar was "Focusing on Eye Health Science Education, Deepening Collaborative Innovation in Popularization" [1] - The Ningbo Eye Hospital emphasized the importance of eye health in national public health strategy and public health management [1] Group 2 - The seminar initiated the compilation of the "National Eye Health Popularization Guide," aiming to shift eye health education from "expert-led" to "public participation" [2] - Innovations in myopia prevention were shared, including a comprehensive approach combining traditional and Western medicine [2] - Ningbo Eye Hospital introduced the "Medical-School Myopia Prevention Circle" and a graded intervention system, achieving significant results in local schools [2] Group 3 - The seminar concluded with a consensus to integrate resources from various regions to enhance myopia prevention and eye health education efforts [3] - Participants visited local schools and the Ningbo Eye Health Science Popularization Museum to observe practical implementations [3]

Core Viewpoint - Aier Eye Hospital (300015) and a research team from Nankai University have achieved a significant breakthrough in treating dry eye syndrome related to Sjögren's syndrome through the development of a "ROS-responsive microneedle patch" [1] Group 1 - The research findings were published in the international academic journal "Advanced Science" [1] - The paper was selected as the cover article for Volume 12, Issue 16, scheduled for publication on April 24, 2025, due to its innovation and academic value [1] - This breakthrough offers new treatment hope for patients suffering from dry eye syndrome related to Sjögren's syndrome (SSDE) [1]

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of He Shi Eye Hospital Group, indicating a recent stock price increase and a decline in shareholder numbers [1][2] - As of May 16, the closing stock price of He Shi Eye Hospital was 20.78 yuan, up by 1.02%, with a latest price-to-book ratio of 1.72, marking a new low in 13 days and a total market capitalization of 3.284 billion yuan [1] - The company reported a revenue of 291 million yuan for Q1 2025, representing a year-on-year increase of 2.35%, and a net profit of 32.53 million yuan, which is a 12.27% increase year-on-year, with a gross profit margin of 43.80% [1] Group 2 - The company has 9,399 shareholders as of March 31, 2025, a decrease of 392 shareholders from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - He Shi Eye Hospital's main business focuses on personalized and intelligent eye health management services, including refractive surgery, cataract treatment, retinal disease treatment, and other eye disease treatments [1] - The company's price-to-earnings (P/E) ratio is significantly lower than the industry average, with a trailing P/E of -137.73 compared to the industry average of 37.33 [2]

普瑞眼科2025年第一季度报告显示，普瑞眼科报告期内营业总收入为7.42亿元，同比增长9.82%；归属 于上市公司股东的净利润为2727.94万元，同比增长61.18%；归属于上市公司股东的扣除非经常性损益 的净利润为2831.55万元，同比增长48.37%；经营活动产生的现金流量净额为1.95亿元。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 742. 251. 316. 24 | 675,882,973,16 | | 9.82% | | 归属于上市公司股东的净利 | 27, 279, 356. 63 | 16, 924, 936, 43 | | 61. 18% | | 润(元) | | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 28, 315, 487, 26 | 19,084,077.60 | | 48. 37% | | (元) | | | | | | 经营活动产生的现金流量净 额(元) | 194. 676. 885. 40 | 12 ...

接到举报后，南通市纪委监委组成了工作专班，对相关问题进 行了全面彻查。目前，已依规依纪对有关涉事人员进行了严格 处理。 作者：张铃 封图：图虫创意 同时，艾芬亦对爱尔眼科员工提起过诉讼。艾芬曾起诉爱尔眼科职工段某民、刘某菲、刘某等侵犯 名誉权，2025年4月，武汉市江汉区人民法院一审判决艾芬胜诉 。 在该一审判决前后 ，艾芬的 微博账号"急诊向日葵艾芬"被封。 南通爱尔眼科医院是爱尔眼科（300015.SZ）旗下医院。爱尔眼科成立于2003年，是中国眼科龙 头，截至2024年底，爱尔眼科在全球范围内共有974家品牌医院、眼科中心及诊所，其中811家 在中国内地。此前，爱尔眼科董事长陈邦曾于2022年初发内部信，称将全面拥抱社会监督。 艾芬曾在抗击新冠疫情中作出积极贡献，民间评价其为"疫情发哨人"。2020年5月，艾芬因白内 障在武汉爱尔眼科医院进行了人工晶体植入手术，术后5个月出现右眼视网膜脱落，12月其申诉右 眼几乎失明，质疑医院存在违规操作。爱尔眼科则称，艾芬视网膜脱离与医院手术没有直接关联。 有关部门曾就该事件成立调查组，爱尔眼科称，艾芬不同意进行医疗鉴定、不走法律程序。 艾芬多次在社交平台质疑爱尔眼科 ...

5月15日，经济观察报获悉，南通爱尔眼科（300015）医院党支部书记、CEO于文娟被南通市崇川区纪 委给与党纪处分，同时，南通市崇川区政协撤销了于文娟的政协委员身份。 艾芬多次在社交平台质疑爱尔眼科的诊疗及管理问题，相关内容不仅关涉自身，也涉及其他曾在爱尔眼 科就诊的患者。 同时，艾芬亦对爱尔眼科员工提起过诉讼。艾芬曾起诉爱尔眼科职工段赛民、刘语菲、刘峰等侵犯名誉 权，2025年4月，武汉市江汉区人民法院一审判决艾芬胜诉。在该一审判决前后，艾芬的微博账号"急诊 向日葵艾芬"被封。 经济观察报注意到，《举报信》提到，南通市多名公职人员曾接受于文娟宴请。南通爱尔眼科医院一些 内部员工给艾芬提供了相应证据，包括南通爱尔眼科多份招待明细表，其中一些招待明细表的招待原因 标明为"业务拜访""业务拓展"。 南通爱尔眼科医院是爱尔眼科（300015.SZ）旗下医院。爱尔眼科成立于2003年，是中国眼科龙头，截 至2024年底，爱尔眼科在全球范围内共有974家品牌医院、眼科中心及诊所，其中811家在中国内地。此 前，爱尔眼科董事长陈邦曾于2022年初发内部信，称将全面拥抱社会监督。 艾芬曾在抗击新冠疫情中作出积极贡献，民间 ...

投资者关系活动记录表 编号：2025-003 | | □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 | | --- | --- | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及人员 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与 | | 姓名 | 厦门辖区上市公司 2024 年年报业绩说明会暨投资者网上集体 | | | 接待日活动的投资者 | | 时间 | 2025 年 5 月 15 日（周四）下午 15:40~17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 陈凤国先生 董事 | | | 陈鹭燕女士 财务总监 | | 上市公司接待人员 姓名 | 曹乃恩先生 董事会秘书 | | | 王志强先生 独立董事 | | | 赵 冀先生 保荐代表人 | | | 1、请问一下 年公司，持续发展和业务开展做了哪些调 25 | | | 整和创新？ | | | 尊敬的投资者您好，感谢您对华厦眼科的关注。从 2025 | | | 年起，公司将按照《华 ...

中证报中证网讯(王珞)日前，2025未来医疗医药100强展会在苏州举行，何氏眼科（301103）受邀参 加。何氏数字医疗首席科学家、辽宁何氏医学院视觉智能中心主任何星儒在演讲时表示，近年来，何氏 眼科围绕全球眼健康总体方向，以构建"智慧光明城"为战略目标，依托眼健康全产业链生态平台优势， 借助大数据、人工智能、基因、干细胞等新技术，通过精准医疗和智慧医疗赋能，为患者提供数字化、 全方位、全场景、全生命周期的眼健康管理服务新模式，持续提升基层眼科医疗服务能力。 何星儒分享了何氏眼科通过大数据和人工智能等新技术赋能近视防控、糖尿病眼病防治及社区防盲公共 卫生模式搭建的成果与经验，充分落地应用数字化技术，推动其在眼科公共卫生领域中发挥更大价值。 近年来，何氏眼科将数字技术、人工智能与公益相结合，将专业医疗技术和百姓需求相结合，持续搭建 布局广泛的基层眼科医疗服务网络，加快推进"何氏智慧眼健康管理站"和"光明小屋"建设，以眼科智能 设备为入口，通过AI智能诊断，结合专家线上看诊，实现了眼部疾病和慢性疾病早监测、早预警、早 干预、早治疗，真正让数据多跑路、群众少跑腿，打通基层眼保健的"最后一公里"，有力提升了眼健康 公 ...

5月13日，辽宁省委省政府对在2024年辽宁全面振兴新突破三年行动攻坚之年作出突出贡献的241户企业予以 通报表扬，何氏眼科（301103）连续第二年荣获此殊荣。 2024年以来，扎根辽宁30年的何氏眼科以科技创新蓄势赋能，增强发展实力，提升服务能力，推动眼健康服 务向智能化、精准化和普惠化转型，助力健康辽宁和数字辽宁建设。 何氏眼科围绕"健康中国"战略和全球眼健康总体方向，以构建"智慧光明城"为战略目标，发挥独有的眼健康 全产业链生态平台优势，借助大数据、人工智能、基因、干细胞等新技术，通过精准医疗和智慧医疗赋能， 加快发展新质生产力，全面开启数字化、全方位、全场景、全生命周期眼健康管理的服务新模式，不断满足 人民群众多层次多样化眼健康和大健康需求。 为切实提高儿童青少年视力健康水平，作为辽宁省青少年近视防控基地，何氏眼科通过科技创新和模式探 索，构建了辽宁特色的"365近视防控体系"。 此外，何氏眼科将数字技术、人工智能与公益相结合，专业医疗技术和百姓需求相结合，持续在辽宁全省范 围内搭建布局广泛的基层眼科医疗服务网络。公司实施的"光明小屋"项目在2024年全国首届社会办医"新质生 产力"案例大赛中荣膺服 ...